Introduction Founded in 1973, Hanmi Pharmaceuticals has evolved into one of the top pharmaceutical companies in terms of revenue and has consistently invested heavily in research and development, making it the most R&D-focused company in its industry. With a history of adaptability and strategic partnerships with multinational and biotech companies, Hanmi has successfully transitioned from generic drugs to innovative small molecules and biologics. Together, Hanmi and Beijing Hanmi are collaborating on various business opportunities, new drug development projects, and sales and marketing in Chinese territories. As the only Asian company with a strong presence in both Korea and China, and with a commitment to open innovation through strategic collaborations, Hanmi is dedicated to providing differentiated treatment options for patients suffering from various diseases. |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 48 |
Bispecific antibody | 6 |
Synthetic peptide | 5 |
Unknown | 4 |
Enzyme | 3 |
Top 5 Target | Count |
---|---|
4-1BB x PDL1 | 2 |
GCGR x GIPR x GLP-1R | 2 |
AT1R x VDCCs | 2 |
GCGR(Glucagon receptor) | 2 |
TEAD x YAP1 | 2 |
Target |
Mechanism CSF-3R agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. KR |
First Approval Date18 Mar 2021 |
Target |
Mechanism SRC inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date14 Dec 2020 |
Mechanism HMG-CoA reductase inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date26 Mar 2019 |
Start Date01 Aug 2024 |
Sponsor / Collaborator |
Start Date28 May 2024 |
Sponsor / Collaborator |
Start Date17 May 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Atorvastatin Calcium Hydrate/Irbesartan ( AT1R x HMG-CoA reductase ) | Hypertension More | Approved |
Clopidogrel napadisilate ( P2Y12 receptor ) | Thrombosis More | Approved |
Tamsulosin Hydrochloride ( α1A-AR ) | Prostatic Hyperplasia More | Approved |
Propranolol Hydrochloride ( β-adrenoceptors ) | Hemangioma More | Approved |
Amlodipine Camsylate ( VDCCs ) | Hypertension More | Approved |